Chitosan Nanoparticle Gene Delivery for Gut Mucosa
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Chitosan-based nanoparticles face challenges in achieving long-term expression and transfection of therapeutic nucleic acids in gut mucosal cells due to poor stability, solubility, and low transfection efficiency, particularly in the harsh environment of the gut, where short-lived cells and rapid cell turnover hinder sustained gene expression and systemic protein delivery.
Innovation Solution
Development of chitosan-based nanoparticles with molecular weights between 3kDa and 250kDa, optimized N:P ratios, and expression control regions that enable long-term, regulatable expression of therapeutic nucleic acids in gut mucosal cells, including endocrine cells, by forming stable complexes that can persistently produce therapeutic proteins in the systemic circulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If large molecular weight chitosan is used to form stable complexes with DNA, then complex stability is improved, but transfection efficiency deteriorates due to poor uptake and release of DNA
Solution Approach 1:
The patent applies parameter changes by optimizing the molecular weight of chitosan to a specific range (5-50 kDa) and controlling the N:P ratio (5:1 to 20:1) to achieve the optimal balance between complex stability and transfection efficiency. This resolves the contradiction by identifying specific parameter values that satisfy both requirements simultaneously.
2Quantity of substance
If low molecular weight chitosan is used to improve solubility, then solubility is improved, but complex stability deteriorates and transfection efficiency remains low
Solution Approach 1:
The patent resolves this contradiction by establishing an optimal molecular weight range (5-50 kDa) that provides sufficient solubility while maintaining adequate complex stability. This specific parameter range balances the competing requirements of solubility and stability.
3Ease of operation
If chitosan/DNA complexes are administered orally to transfect gut epithelial cells, then in vivo transfection is achieved, but transfection efficiency deteriorates due to rapid cell turnover every 3-5 days
Solution Approach 1:
The patent applies preliminary action by targeting and transfecting stem cells and progenitor cells in the gut before they differentiate into short-lived epithelial cells. By delivering therapeutic nucleic acids to long-lived stem cells (which have turnover times of months to years), the treatment achieves sustained expression despite the rapid turnover of differentiated epithelial cells.
4Object-affected harmful factors
If conventional chitosan complexes are used for gene delivery, then non-viral delivery is achieved, but transfection efficiency deteriorates compared to viral methods
Solution Approach 1:
The patent applies composite materials by formulating optimized chitosan/DNA complexes with specific molecular weight ranges and N:P ratios that enhance transfection efficiency while maintaining the safety advantages of non-viral delivery. The composite structure achieves viral-level efficiency without the associated safety risks.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanoparticles achieve sustained, dynamic expression of therapeutic proteins for extended periods, overcoming the limitations of short-lived cells and rapid turnover in the gut, effectively increasing systemic protein levels and providing therapeutic effects.
Implementation Method 1
Chitosan is a non-toxic cationic copolymer... chitosan-based nanoparticles comprising therapeutic nucleic acids... forming stable complexes
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides chitosan-based nanoparticles that can protect nucleic acids and deliver the same into gut mucosal cells. Compositions and methods for the expression of therapeutic nucleic acids in cells of the gut mucosa are provided. Compositions and methods for delivering therapeutic proteins systemically from cells of the gut mucosa are also provided.